SML3967

Levonorgestrel

≥98% (HPLC)

• Sinónimos: (17α)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one, 13-Ethyl-17-ethynyl-17β-hydroxy-4-gonen-3-one, 13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one, D(−)-Norgestrel, D-Norgestrel, LNG
• Fórmula empírica (notación de Hill): C₂₁H₂₈O₂
• Número de CAS: 797-63-7
• Peso molecular: 312.45
• MDL number: MFCD01546387
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D -28 to -36° (C= 1.0g/100 ml in CDCl3)
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: O[C@@]1([C@@]2([C@H]([C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC2)CC1)CC)C#C
• InChI key: WWYNJERNGUHSAO-XUDSTZEESA-N

Descripción

Biochem/physiol Actions

Orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus.

Levonorgestrel (D-Norgestrel) is an orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus. Levonorgestrel inhibits the release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). D(−)-Norgestrel prevents fertilization by altering cervical mucus consistency, and interfering with the endometrial lining, making it less receptive to implantation. Levonorgestrel (LNG) can be used alone or in combination with estrogen during hormone replacement therapy.

Información de seguridad

• pictograms: GHS08
• signalword: Danger
• hcodes: H351,H360D,H362
• pcodes: P202 - P260 - P263 - P264 - P280 - P308 + P313
• Hazard Classifications: Carc. 2 - Lact. - Repr. 1A
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable